MétaCan
Menu
Back to cohort
Record W3175102295 · doi:10.2337/db21-455-p

455-P: Global Comparisons of Awareness of Chronic Kidney Disease and Renoprotective Therapies among Type 1 Diabetes Patients

2021· article· en· W3175102295 on OpenAlexaboutno aff
Emily Ye, Julia Stevenson, Jacqueline Tait, REBECCA GOWEN, Sara Suhl, Caterina Florissi, Christianne Pang, Richard Wood

Bibliographic record

VenueDiabetes · 2021
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineKidney diseaseDiabetes mellitusType 2 diabetesDiseaseType 1 diabetesRenal replacement therapyInternal medicinePediatricsFamily medicineIntensive care medicineEndocrinology

Abstract

fetched live from OpenAlex

Chronic kidney disease (CKD) is a long-term complication of diabetes affecting millions of people worldwide. CKD screening is recommended annually for patients with type 1 diabetes (T1D) with duration of ≥5 years. Diabetes drugs like SGLT-2 inhibitors, approved for T1D patients in Europe but not in the US, have been found to improve renal outcomes. In this study, from September-November 2020, adults with T1D in the US (n=1,561), Canada (n=350), Italy (n=301), Sweden (n=120), Germany (n=380), France (n=298), UK (n=370), and Netherlands (n=180) from an opted-in research panel rated their level of agreement with statements about CKD risk and renoprotective therapies. Health and demographic information were also collected. More respondents in the US, Italy, and Canada strongly agreed that diabetes increases CKD risk than those in Sweden, UK, and Netherlands (61%, 58%, 57% vs. 44%, 42%, 38%). Across most countries, PWD who had received a screening for CKD were more likely to strongly agree that having diabetes increases CKD risk. In the US, Canada, Sweden, and the UK, those who had been screened were more likely to indicate awareness of diabetes drugs’ renoprotective benefits; however, overall awareness was low, especially among European respondents. This data emphasizes the importance of regular screenings and improving awareness among patients to prevent CKD and further complications.View largeDownload slideView largeDownload slide DisclosureE. Ye: Other Relationship; Self; dQ&A. J. Stevenson: Other Relationship; Self; Abbott, Ascensia Diabetes Care, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, LifeScan, Medtronic, Roche Diabetes Care, Senseonics, Tandem Diabetes Care. J. Tait: Other Relationship; Self; dQ&A Market Research Inc. R. Gowen: Other Relationship; Self; dQ&A. S. Suhl: Other Relationship; Self; dQ&A has several clients (>10) in the diabetes field. C. Florissi: Other Relationship; Self; Abbott Diabetes, Ascensia Diabetes Care, Dexcom, Inc., Insulet Corporation, LifeScan, Lilly Diabetes, Medtronic, Roche Diabetes Care, Senseonics, Tandem Diabetes Care. C. Pang: Employee; Self; dQ&A Market Research Inc. R. Wood: Research Support; Self; Abbott Diabetes, American Diabetes Association, Ascensia Diabetes Care, Boehringer Ingelheim International GmbH, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk Inc., Sanofi.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.007
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.014
Threshold uncertainty score0.027

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.007
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0020.003
Science and technology studies0.0010.000
Scholarly communication0.0010.001
Open science0.0010.002
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.248
Teacher spread0.237 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueDiabetesSame topicDiabetes Treatment and ManagementFrench-language works237,207